Details of our research group are available at https://alexkentsis.net/. Recently, we’ve used protein engineering and proteomic approaches to develop first-in-class peptidic inhibitors of transcription factor MYB (PMID: 29317678, PMID: 33527899), as well as novel methods in functional proteomics and mass spectrometry (PMID: 28821601, PMID: 31083951, PMID: 33749263). We have now extended these approaches to develop a novel peptide interference screening platform, optimally suited for the study of fusion oncoproteins and development of direct peptidomimetic inhibitors.

As a post-doctoral research fellow, you will leverage an integrated team of researchers using functional proteomics, protein engineering, diverse cell and animal cancer models, and the dynamic intellectual environment of MSK. An ideal candidate is a PhD graduate with experience in biochemistry, protein engineering, or structural biology. Knowledge of cancer biology is preferred.

Excellent communication and project managements skills are essential. New ideas and interdisciplinary approaches are encouraged. MSK and Tri-I provide a dynamic, nurturing, and inspiring training environment.

Please send a cover letter describing your interests and CV to Alex Kentsis, MD, PhD at the Molecular Pharmacology Program, Sloan Kettering Institute at kentsisresearchgroup+application@gmail.com.

The post Post-doctoral research fellow in functional protein engineering in the Kentsis Research Group at the Memorial Sloan Kettering Cancer Center appeared first on Kentsis Research Group at Memorial Sloan Kettering Cancer Center.

We are a group of physicians and scientists in the Molecular Pharmacology Program at the Sloan Kettering Institute and Department of Pediatrics and the Tow Center for Developmental Oncology at the Memorial Sloan Kettering Cancer Center.

We leverage proteomics to develop improved biologic therapies, computational modeling to define oncogenic mechanisms, and innovative mouse models to determine biological functions and guide clinical trials of improved treatments, particularly for children with refractory cancers.

We are developing functional mass spectrometry proteomics methods to define oncogenic signaling, and develop new macromolecular cancer drugs. In particular, we have been using peptide barcoding to construct libraries of cell-penetrant peptidomimetic inhibitors of oncogenic proteins. Recently, we used this approach to successfully develop the first effective inhibitor of MYB, an essential oncoprotein in the majority of blood cancers, as recently published in Nature Communications 2018 and Elife 2021. Current efforts are focused on applying this technology for protein engineering and development of new peptide conjugates for cancer and gene therapy.

An ideal candidate is a PhD graduate with experience in analytical chemistry or protein engineering, who is interested in developing an independent research programme for future faculty or scientist positions in biotechnology and drug design.

We value diversity in ideas and people, and our group seeks excellence and equity in scientific discourse and scientific practice. Memorial Sloan Kettering Cancer Center is a vibrant academic community, part of the Tri-Institutional campus with Rockefeller University and Weill Cornell Medical College, located in the middle of Manhattan in New York City. We offer a unique and unparalleled research environment in cancer biology and oncology with diverse basic and applied science programs, which are directly integrated with clinical care, enabling rapid translation of improved therapies for patients.

Please send a detailed cover letter describing your past research and interests and current CV to Alex Kentsis, MD, PhD at kentsisresearchgroup+application@gmail.com.

The post Post-doctoral Research Fellow in Cancer Drug Design appeared first on Kentsis Research Group at Memorial Sloan Kettering Cancer Center.

We are a group of biochemists, biologists and physicians in the Molecular Pharmacology Program at the Sloan Kettering Institute in New York City, USA. We carry out research in cancer biology, and our current work is focused on the phenomenon of cellular plasticity, as it relates both to the fundamental mechanisms of cancer pathogenesis and emerging rational therapies.

In particular, we are studying the biology of refractory leukemias and solid tumors, and we are interested in understanding the principles of disorganization of their genomes and proteomes, and determining the molecular mechanisms of response and adaptation of tumor cells to targeted therapies.

To answer these questions, we are developing new approaches, based on quantitative mass spectrometry and functional proteomics, to decipher the mechanisms of cancer cell signaling and develop new therapeutics. Two projects are immediately available for talented and ambitious recent PhD graduates:

Forward Proteomic Screens for Cancer Therapeutics and Macromolecular Delivery. Using recently developed methods for quantitative proteomics and peptide barcoding (Egloff et al, Nature Methods 2019, PMID: 31113958), we’ve developed a new platform for high-throughput design and screening of macromolecular cell penetration and delivery reagents. This is a transformative technology that enables the generation of new classes of drugs to modulate specific protein-protein interactions, which we’ve recently applied for targeted leukemia therapy (Ramaswamy et al, Nature Communications 2018, PMID 29317678). Current efforts are focused on applying this technology for protein engineering and development of new peptide conjugates for cancer and gene therapy.

Quantitative Cell Proteomics Atlas (http://qcpa.mskcc.org). Using recently optimized methods for ultra-sensitive quantitative proteomics (Cifani & Kentsis, MCP 2017, PMID 28821601), we’ve developed an atlas of targeted mass spectrometry assays to profile biochemical signaling at the pathway scale in normal and cancer cells. Current efforts are focused on developing high-throughput and genome-scale methods. This work aims to define systems-level mechanisms of aberrant signaling in cancer cells, as well as fundamental cell biological processes of signaling adaptation, feedback and integration.

If you are a recent PhD graduate with interest in the above areas and experience with nanoscale liquid chromatography, electrospray ionization, high-resolution mass spectrometry or protein engineering and chemistry, please email Alex Kentsis at kentsisresearchgroup+application@gmail.com

Requirements

An ideal candidate is a PhD graduate with experience in mass spectrometry, analytical chemistry or protein engineering, who is interested in developing an independent research programme or future positions in biotechnology in functional proteomics.

Hands-on experience with the operation of high-resolution mass spectrometers and nanoscale chromatographs, design of experiments using quantitative proteomics or experience in biochemistry and protein engineering are essential.

Please send a cover letter describing your interests, CV, and 3 letters of reference to Alex Kentsis, MD, PhD at the Molecular Pharmacology Program, Sloan Kettering Institute.

The post Post-Doctoral Research Fellow in Functional Cancer Proteomics appeared first on Kentsis Research Group at Memorial Sloan Kettering Cancer Center.

This post-doctoral research position will leverage an integrated team of researchers using functional genomics and proteomics, next-generation sequencing and genome assembly, and dynamic intellectual environment of the SKI.

An ideal candidate is a PhD graduate with experience in computer science, bioinformatics, next-generation sequencing, and genome assembly. Proficiency with object-oriented and scripting programming languages, numerical analysis, and software engineering are preferred.

Excellent communication and project managements skills are essential. Please send a cover letter describing your interests, CV, and 3 letters of reference to Alex Kentsis, MD, PhD at the Molecular Pharmacology & Chemistry Program, Sloan-Kettering Institute.

The post Position for a Post-Doctoral Research Fellow in Functional Cancer Genomics appeared first on Kentsis Research Group at Memorial Sloan Kettering Cancer Center.

This post-doctoral research position will leverage an integrated team of researchers using functional genomics and proteomics, dedicated multi-dimensional nanoscale liquid chromatographs and high-resolution mass spectrometers, and dynamic intellectual environment of the Sloan-Kettering Institute. The work will 1) develop a new instrumental platform with superior sensitivity for the analysis of non-canonical and functionally modified proteins in cancer cells, and 2) investigate the mechanisms of aberrant kinase signaling and gene expression required for leukemogenesis in primary human and genetically-engineered mouse leukemia cells in vivo.

An ideal candidate is a PhD graduate with experience in mass spectrometry and analytical chemistry, who is interested in developing an independent research programme in functional cancer proteomics.

Hands-on experience with the operation of high-resolution mass spectrometers and nanoscale chromatographs, and design of experiments using quantitative proteomics are essential. Please send a cover letter describing your interests, CV, and 3 letters of reference to Alex Kentsis, MD, PhD at the Molecular Pharmacology & Chemistry Program, Sloan-Kettering Institute.

The post Position for a Post-Doctoral Research Fellow in Functional Cancer Proteomics appeared first on Kentsis Research Group at Memorial Sloan Kettering Cancer Center.

An ideal candidate is an individual with at least 3 years of biological laboratory research expertise, including hands-on experience with breeding of genetically-engineered mice, mouse husbandry and procedures such as autopsy and xenografting, mammalian tissue culture, and lentivirus transduction, as well as analytical experiments in molecular and cell biology such as genetic cloning, immunoassays, and molecular purifications.

Please read the full advertisement and apply online.

The post Position for a Senior Research Technician appeared first on Kentsis Research Group at Memorial Sloan Kettering Cancer Center.